This exploratory analysis of a phase 1b study evaluating BIIB080, a MAPT-targeting antisense oligonucleotide, in mild Alzheimer’s disease indicates favorable trends of high-dose BIIB080 in slowing cognitive and functional decline, supporting the need for future trials evaluating clinical efficacy of BIIB080 in mild Alzheimer’s disease.
- Melanie Shulman
- Shuang Wu
- Diana Gallagher
